Literature DB >> 25884277

Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis.

Baishali Chaudhury1, Mu Zhou1, Dmitry B Goldgof1, Lawrence O Hall1, Robert A Gatenby2, Robert J Gillies2, Bhavika K Patel2, Robert J Weinfurtner2, Jennifer S Drukteinis2.   

Abstract

PURPOSE: To evaluate heterogeneity within tumor subregions or "habitats" via textural kinetic analysis on breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for the classification of two clinical prognostic features; 1) estrogen receptor (ER)-positive from ER-negative tumors, and 2) tumors with four or more viable lymph node metastases after neoadjuvant chemotherapy from tumors without nodal metastases.
MATERIALS AND METHODS: Two separate volumetric DCE-MRI datasets were obtained at 1.5T, comprised of bilateral axial dynamic 3D T1 -weighted fat suppressed gradient recalled echo-pulse sequences obtained before and after gadolinium-based contrast administration. Representative image slices of breast tumors from 38 and 34 patients were used for ER status and lymph node classification, respectively. Four tumor habitats were defined based on their kinetic contrast enhancement characteristics. The heterogeneity within each habitat was quantified using textural kinetic features, which were evaluated using two feature selectors and three classifiers.
RESULTS: Textural kinetic features from the habitat with rapid delayed washout yielded classification accuracies of 84.44% (area under the curve [AUC] 0.83) for ER and 88.89% (AUC 0.88) for lymph node status. The texture feature, information measure of correlation, most often chosen in cross-validations, measures heterogeneity and provides accuracy approximately the same as with the best feature set.
CONCLUSION: Heterogeneity within habitats with rapid washout is highly predictive of molecular tumor characteristics and clinical behavior.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  axillary lymph node metastases; breast cancer; estrogen receptor; habitats; magnetic resonance imaging; textural kinetics

Mesh:

Substances:

Year:  2015        PMID: 25884277      PMCID: PMC5017794          DOI: 10.1002/jmri.24921

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  33 in total

1.  Assessing heterogeneity of lesion enhancement kinetics in dynamic contrast-enhanced MRI for breast cancer diagnosis.

Authors:  A Karahaliou; K Vassiou; N S Arikidis; S Skiadopoulos; T Kanavou; L Costaridou
Journal:  Br J Radiol       Date:  2010-04       Impact factor: 3.039

Review 2.  Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI.

Authors:  Erez Eyal; Hadassa Degani
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

3.  Volumetric texture analysis of breast lesions on contrast-enhanced magnetic resonance images.

Authors:  Weijie Chen; Maryellen L Giger; Hui Li; Ulrich Bick; Gillian M Newstead
Journal:  Magn Reson Med       Date:  2007-09       Impact factor: 4.668

4.  Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.

Authors:  Daniel I Golden; Jafi A Lipson; Melinda L Telli; James M Ford; Daniel L Rubin
Journal:  J Am Med Inform Assoc       Date:  2013-06-19       Impact factor: 4.497

5.  Characterization of spatiotemporal changes for the classification of dynamic contrast-enhanced magnetic-resonance breast lesions.

Authors:  Jana Milenković; Kristijana Hertl; Andrej Košir; Janez Zibert; Jurij Franc Tasič
Journal:  Artif Intell Med       Date:  2013-03-30       Impact factor: 5.326

6.  Outcome of combined modality treatment including neoadjuvant chemotherapy of 128 cases of locally advanced breast cancer: data from a tertiary cancer center in northern India.

Authors:  V Raina; M Kunjahari; N K Shukla; S V S Deo; A Sharma; B K Mohanti; D N Sharma
Journal:  Indian J Cancer       Date:  2011 Jan-Mar       Impact factor: 1.224

Review 7.  Breast cancer intratumor genetic heterogeneity: causes and implications.

Authors:  Charlotte K Y Ng; Helen N Pemberton; Jorge S Reis-Filho
Journal:  Expert Rev Anticancer Ther       Date:  2012-08       Impact factor: 4.512

8.  Estrogen receptor and breast MR imaging features: a correlation study.

Authors:  Jeon-Hor Chen; Hyeon-Man Baek; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

Review 9.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

10.  The value of T2* in differentiating metastatic from benign axillary lymph nodes in patients with breast cancer--a preliminary in vivo study.

Authors:  Chuanming Li; Shan Meng; Xinhua Yang; Jian Wang; Jiani Hu
Journal:  PLoS One       Date:  2014-01-16       Impact factor: 3.240

View more
  30 in total

1.  Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging.

Authors:  Tianwen Xie; Qiufeng Zhao; Caixia Fu; Qianming Bai; Xiaoyan Zhou; Lihua Li; Robert Grimm; Li Liu; Yajia Gu; Weijun Peng
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

Review 2.  Spatial Heterogeneity in the Tumor Microenvironment.

Authors:  Yinyin Yuan
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

3.  Multiparametric MRI and Coregistered Histology Identify Tumor Habitats in Breast Cancer Mouse Models.

Authors:  Bruna V Jardim-Perassi; Suning Huang; William Dominguez-Viqueira; Jan Poleszczuk; Mikalai M Budzevich; Mahmoud A Abdalah; Smitha R Pillai; Epifanio Ruiz; Marilyn M Bui; Debora A P C Zuccari; Robert J Gillies; Gary V Martinez
Journal:  Cancer Res       Date:  2019-06-11       Impact factor: 12.701

4.  Oxygen-Guided Radiation Therapy.

Authors:  Boris Epel; Matthew C Maggio; Eugene D Barth; Richard C Miller; Charles A Pelizzari; Martyna Krzykawska-Serda; Subramanian V Sundramoorthy; Bulent Aydogan; Ralph R Weichselbaum; Victor M Tormyshev; Howard J Halpern
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-08       Impact factor: 7.038

5.  Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Jia Wu; Guanghua Gong; Yi Cui; Ruijiang Li
Journal:  J Magn Reson Imaging       Date:  2016-04-15       Impact factor: 4.813

6.  Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer.

Authors:  Ming Fan; Peng Zhang; Yue Wang; Weijun Peng; Shiwei Wang; Xin Gao; Maosheng Xu; Lihua Li
Journal:  Eur Radiol       Date:  2019-01-07       Impact factor: 5.315

7.  Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status.

Authors:  Shinn-Huey S Chou; Eva C Gombos; Sona A Chikarmane; Catherine S Giess; Jagadeesan Jayender
Journal:  J Magn Reson Imaging       Date:  2017-04-03       Impact factor: 4.813

Review 8.  Targeting acidity in cancer and diabetes.

Authors:  Robert J Gillies; Christian Pilot; Yoshinori Marunaka; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-30       Impact factor: 10.680

Review 9.  Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow.

Authors:  Robert J Gillies; Joel S Brown; Alexander R A Anderson; Robert A Gatenby
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

10.  Subregional Radiomics Analysis of PET/CT Imaging with Intratumor Partitioning: Application to Prognosis for Nasopharyngeal Carcinoma.

Authors:  Hui Xu; Wenbing Lv; Hui Feng; Dongyang Du; Qingyu Yuan; Quanshi Wang; Zhenhui Dai; Wei Yang; Qianjin Feng; Jianhua Ma; Lijun Lu
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.